Among the worst performers in the SBF 120, Valneva shares fall 4.5% following Ixchiq setback

Valneva's (VALN) shares fell after the UK revoked approval for its Ixchiq chikungunya vaccine due to safety and benefit-risk concerns. The decision does not affect other markets and is not expected to significantly impact sales. Valneva will not appeal, focusing on endemic regions instead.

Valneva's shares fell 6.6% to €2.435 after the UK revoked its chikungunya vaccine's marketing authorization. The company stated this was based on known safety data and expects negligible financial impact. Approvals in the EU, Canada, and Brazil remain. The CAC 40 also declined due to rising oil prices and U.S. Treasury yields.

Valneva SE (VALN) shares dropped after the UK revoked approval for its Ixchiq chikungunya vaccine. The decision, based on a benefit-risk assessment, does not affect Ixchiq's licenses in other territories. Valneva expects minimal financial impact and will not appeal. The company cites positive safety data from other regions.

Valneva SE (VALN) shares fell ~5% after the UK revoked the marketing authorization for its chikungunya vaccine, Ixchiq, due to safety concerns, according to the company. The vaccine was launched in 2023 and is the first of its kind. The move impacts Valneva's revenue and market position in the vaccine sector.

Valneva's stock (VALN) fell 7% after hours as the UK revoked authorization for its IXCHIQ vaccine. The company had previously cut its 2026 sales outlook to €135M-€150M, citing weak demand. VALN stock is down 33% year-to-date, with neutral retail sentiment.

Valneva SE ADR stock fell 5.9% to $5.53 after the UK revoked its chikungunya vaccine's marketing authorization. The company stated the financial impact is limited and no recall costs are expected. The European Medicines Agency and Health Canada maintained the vaccine's authorizations. The stock is trading near its 52-week low of $4.75.